US › Healthcare

Regenxbio Inc (RGNX)

US · Healthcare · Biotechnology

$10.30+3.41%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$6.4M
Revenue YoY
-92.8%
Net profit
$-90.1M
Profit YoY
-1580.4%
EPS
$-1.72
EPS estimate
$-1.41
Net margin
-1,408.6%

EPS came in at -1.72 against a street estimate of -1.41 — a miss of 22.0%.

Key statistics

Market cap
$620.4M
Forward P/E
0.0
P/B
29.43
Book value
$0.41
EPS (TTM)
$-5.60
52-week high
$16.19
52-week low
$5.46
50-day MA
$9.46
200-day MA
$10.57
Beta
0.94

Analyst view

Analysts rate Regenxbio Inc a buy (11 buy, 1 hold, 0 sell out of 12) with an average price target of $24.27.

Shareholding

Insiders
6.59%
Institutions
66.86%

Largest institutional holders

FundStake
BlackRock Inc9.03%
Redmile Group, LLC6.82%
JPMorgan Chase & Co5.44%
State Street Corp4.27%
Morgan Stanley - Brokerage Accounts3.23%
Vanguard Capital Management, LLC3.14%
The Goldman Sachs Group Inc2.87%
Integral Health Asset Management, LLC2.34%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Regenxbio Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.